Table 4. Post-Transplant Study: Comparison of AMR and non-AMR patient characteristics.
| AMR | Non-AMR | P value | |
|---|---|---|---|
| Sample Size | 12 | 19 | |
| Male | 75% (9/12) | 68% (13/19) | 1.00 |
| Age at Transplant (Years ± SD) | 40.2 ± 12.7 | 52.4 ± 10.4 | 0.007 |
| Ischemic Cardiomyopathy | 25% (4/12) | 42% (8/19) | 0.71 |
| Pre-Transplant cPRA Class I (% ± SD) | 34 ± 34 | 3 ± 8 | 0.002 |
| Pre-Transplant cPRA Class II (% ± SD) | 28 ± 38 | 2 ± 9 | 0.008 |
| Pre-Transplant VAD | 42% (5/12) | 11% (2/19) | 0.08 |
| Total Rejection Score* | 0.33 ± 0.23 | 0.29 ± 0.14 | 0.48 |
| Time of Sample Post-Transplant (Years ± SD) | 1.92 ± 1.94 | 1.71 ± 0.78 | 0.73 |
| LVEF (% ± SD) | 43 ± 12% | > 60% | 0.003 |
| C4d positive biopsy† | 58% (7/12) | 11% (2/19) | 0.012 |
| DSA | 75% (9/12) | 0% | 0.0001 |
| Prednisone | 83% (10/12) | 84% (16/19) | 1.00 |
| MMF | 92% (11/12) | 68% (13/16) | 0.20 |
| mTOR inhibitor | 33% (4/12) | 26% (5/19) | 0.69 |
| Cyclosporine | 58% (7/12) | 53% (10/19) | 1.00 |
| Tacrolimus | 42% (5/12) | 47% (9/19) | 1.00 |
DSA, donor specific antibody; VAD, ventricular assist device; cPRA, calculated panel-reactive antibody; LVEF, left ventricular ejection fraction; MMF, mycophenolate mofetil; SD, standard deviation.
* Total rejection score calculated as described previously [23].
† Two non-rejectors had transient C4d staining on the biopsy preceding the serum sample. C4d staining was not observed on a subsequent biopsy in these patients.